{"protocolSection":{"identificationModule":{"nctId":"NCT04383938","orgStudyIdInfo":{"id":"A20-11195"},"organization":{"fullName":"Aprea Therapeutics","class":"INDUSTRY"},"briefTitle":"Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies","officialTitle":"Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies"},"statusModule":{"statusVerifiedDate":"2025-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-06-25","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-04-30","type":"ACTUAL"},"completionDateStruct":{"date":"2022-04-30","type":"ACTUAL"},"studyFirstSubmitDate":"2020-05-07","studyFirstSubmitQcDate":"2020-05-11","studyFirstPostDateStruct":{"date":"2020-05-12","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-02-27","resultsFirstSubmitQcDate":"2025-05-12","resultsFirstPostDateStruct":{"date":"2025-05-13","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-05-12","lastUpdatePostDateStruct":{"date":"2025-05-13","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Aprea Therapeutics","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"A phase 1/2, open-label, study to determine the safety and preliminary efficacy of APR-246 in combination with pembrolizumab in subjects with solid tumor malignancies. The study will include a safety lead-in portion followed by a phase 2 expansion portion in specific disease groups.","detailedDescription":"This is a phase 1/2, open-label, study to determine the safety and preliminary efficacy of APR-246 (eprenetapopt) in combination with pembrolizumab in subjects with solid tumor malignancies. In the safety lead-in part of study (phase 1), the safety and the recommended phase 2 dose (RP2D) of APR-246 will be investigated.\n\nIn the expansion part of the study (phase 2), both safety and efficacy for the combination therapy will be investigated in the 3 cohorts."},"conditionsModule":{"conditions":["Bladder Cancer","Gastric Cancer","Non Small Cell Lung Cancer","NSCLC","Urothelial Carcinoma","Advanced Solid Tumor"],"keywords":["Pembrolizumab","APR-246","Aprea","eprenetapopt"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":40,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Safety Lead In-Phase 1 Dose Level 1","type":"EXPERIMENTAL","description":"APR-246 4.5g/d with pembrolizumab 200 mg IV (day 3) every 21 days in patients with advanced non-CNS primary tumors","interventionNames":["Drug: APR-246 (eprenetapopt) + Pembrolizumab"]},{"label":"Expansion 1- Gastric Cancer","type":"EXPERIMENTAL","description":"APR-246 4.5 g/d (days 1-4) with pembrolizumab 200 mg IV (day 3) every 21 days in patients with advanced gastric or GEJ tumors","interventionNames":["Drug: APR-246 (eprenetapopt) + Pembrolizumab"]},{"label":"Expansion 2- Bladder Cancer","type":"EXPERIMENTAL","description":"APR-246 4.5 g/d (days 1-4) with pembrolizumab 200 mg IV (day 3) every 21 days in patients with advanced bladder or urothelial tumors","interventionNames":["Drug: APR-246 (eprenetapopt) + Pembrolizumab"]},{"label":"Expansion 3 -NSCLC","type":"EXPERIMENTAL","description":"APR-246 4.5 g/d (days 1-4) with pembrolizumab 200 mg IV (day 3) every 21 days in patients with advanced NSCLC.","interventionNames":["Drug: APR-246 (eprenetapopt) + Pembrolizumab"]}],"interventions":[{"type":"DRUG","name":"APR-246 (eprenetapopt) + Pembrolizumab","description":"APR-246 D1-4 + Pembrolizumab D3","armGroupLabels":["Expansion 1- Gastric Cancer","Expansion 2- Bladder Cancer","Expansion 3 -NSCLC","Safety Lead In-Phase 1 Dose Level 1"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"To Evaluate the Safety of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumors.","description":"To determine the Frequency of treatment-emergent adverse events (TEAEs), and serious adverse events (SAEs) related to APR-246 in combination with pembrolizumab.","timeFrame":"Through study completion, approximately 1 year"},{"measure":"To Confirm the Recommended Phase 2 Dose (RP2D) for APR-246 in Combination With Pembrolizumab","description":"To determine the dose of APR-246 to be selected for the expansion phase based on the occurence of dose limiting toxicities (DLTs) experienced during the safety assessment period","timeFrame":"Through safety lead in period, during cycle 1 (approximately 21 days)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Signed informed consent form (ICF) and ability to comply with protocol requirements.\n2. Known tumor TP53 mutation status from recent or archival sample.\n3. Histologically and/or cytologically confirmed solid tumor malignancy\n\n   1. Safety lead in- Advanced non-central nervous system (CNS) primary tumors that have progressed after first line treatment, who are intolerant to first line treatment, or who are unable to receive first line treatment, and for whom pembrolizumab, or pembrolizumab-based therapy is considered appropriate\n   2. Expansion 1- Patients with a confirmed diagnosis of advanced gastric or gastroesophageal junction (GEJ) tumors that have progressed after first line treatment, who are intolerant to first line treatment, or who are unable to receive first line treatment\n   3. Expansion 2- Patients with a confirmed diagnosis of advanced bladder/urothelial tumors that have progressed after first line treatment, or who are intolerant to first line treatment, or who are unable to receive first line treatment with cisplatin-based chemotherapy.\n   4. Expansion 3- Confirmed diagnosis of advanced non-small cell lung cancer (NSCLC) previously treated with anti-PD-1 or anti-PD-L1 therapy.\n4. Adequate organ function\n\n   1. Creatinine clearance \\> 30 mL/min\n   2. Total serum bilirubin \\< 1.5 × upper limit of normal (ULN) unless due to Gilbert's syndrome, tumor involvement, hemolysis or considered an effect of regular blood transfusions\n   3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\< 3 × ULN, unless due to involvement by the underlying malignancy.\n5. Projected life expectancy of ≥ 12 weeks.\n6. Age ≥ 18 years at the time of signing the ICF.\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2\n8. In the expansion portion, measurable disease meeting the following criteria:\n\n   1. At least 1 lesion of ≥10 mm in the longest diameter (LD) for a non-lymph node or ≥15 mm in the short-axis diameter for a lymph node that is serially measurable according to RECIST 1.1.\n   2. Lesions that have had external beam radiotherapy or loco-regional therapies such as radiofrequency ablation must show subsequent evidence of substantial size increase (ex. 20% increase in LD) to be deemed a target lesion.\n9. Negative serum or urine pregnancy test prior to study treatment initiation in female subjects of childbearing potential.\n10. Women of childbearing potential and men with female partners of childbearing potential must be willing to use an effective form of contraception\n\nExclusion Criteria:\n\n1. Known history of untreated human immunodeficiency virus (HIV)/HIV with a detectable viral load or active hepatitis B or active hepatitis C infection.\n2. Cardiac abnormalities\n3. Concomitant malignancies or previous malignancies with less than a 1-year disease-free interval at the time of signing consent.\n4. Pregnancy or lactation.\n5. Active uncontrolled systemic infection.\n6. An autoimmune condition requiring ≥ 10 mg (or equivalent corticosteroid) prednisone daily, or any other systemic immunosuppressive treatment within 28 days of first dose of study therapy.\n7. Known history of active tuberculosis.\n8. Current (non-infectious) pneumonitis, or a history of pneumonitis that required steroids.\n9. A live vaccine administered within 30 days of the first dose of study treatment.\n10. Receipt of any investigational product within 14 days or 5 half-lives prior to study treatment initiation, whichever is shortest.\n11. Prior intolerance to pembrolizumab or other anti-PD-1/PD-L1 agents.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Joachim Gullbo, MD","affiliation":"Theradex Oncology","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Mayo Clinic","city":"Phoenix","state":"Arizona","zip":"85054","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"Mayo Clinic","city":"Jacksonville","state":"Florida","zip":"32224","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Massachusetts General Hospital","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Dana Farber Cancer Center","city":"Boston","state":"Massachusetts","zip":"02115","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Mayo Clinic","city":"Rochester","state":"Minnesota","zip":"55902","country":"United States","geoPoint":{"lat":44.02163,"lon":-92.4699}},{"facility":"Washington University","city":"St Louis","state":"Missouri","zip":"63130","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Vanderbilt University","city":"Nashville","state":"Tennessee","zip":"37235","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"MD Anderson Cancer Center","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}}]},"referencesModule":{"references":[{"pmid":"36084396","type":"DERIVED","citation":"Park H, Shapiro GI, Gao X, Mahipal A, Starr J, Furqan M, Singh P, Ahrorov A, Gandhi L, Ghosh A, Hickman D, Gallacher PD, Wennborg A, Attar EC, Awad MM, Das S, Dumbrava EE. Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. ESMO Open. 2022 Oct;7(5):100573. doi: 10.1016/j.esmoop.2022.100573. Epub 2022 Sep 7."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Experimental: Safety Lead In","description":"Patients with advanced solid tumors. APR 4.5 g/day intravenously (IV) on days 1-4 with pembrolizumab 200 mg IV on day 3 in each 21-day cycle"},{"id":"FG001","title":"Experimental: Expansion 1","description":"Patients with advanced gastric cancer. APR 4.5 g/day intravenously (IV) on days 1-4 with pembrolizumab 200 mg IV on day 3 in each 21-day cycle"},{"id":"FG002","title":"Experimental: Expansion 2","description":"Patients with advanced urothelial/bladder cancer. APR 4.5 g/day intravenously (IV) on days 1-4 with pembrolizumab 200 mg IV on day 3 in each 21-day cycle"},{"id":"FG003","title":"Experimental: Expansion 3","description":"Patients with advanced NSCLC. APR 4.5 g/day intravenously (IV) on days 1-4 with pembrolizumab 200 mg IV on day 3 in each 21-day cycle"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"21"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"20"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Baseline characteristics are presented by cohort.","groups":[{"id":"BG000","title":"Experimental: Safety Lead In","description":"Patients with advanced solid tumors. APR 4.5 g/day intravenously (IV) on days 1-4 with pembrolizumab 200 mg IV on day 3 in each 21-day cycle"},{"id":"BG001","title":"Experimental: Expansion 1 Patients With Advanced Gastric Cancer.","description":"Patients with advanced gastric cancer. APR 4.5 g/day intravenously (IV) on days 1-4 with pembrolizumab 200 mg IV on day 3 in each 21-day cycle"},{"id":"BG002","title":"Experimental: Expansion 2","description":"Patients with advanced urothelial/bladder cancer. APR 4.5 g/day intravenously (IV) on days 1-4 with pembrolizumab 200 mg IV on day 3 in each 21-day cycle"},{"id":"BG003","title":"Experimental: Expansion 3 Patients With Advanced NSCLC","description":"Patients with advanced NSCLC. APR 4.5 g/day intravenously (IV) on days 1-4 with pembrolizumab 200 mg IV on day 3 in each 21-day cycle"},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"40"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"58","lowerLimit":"35","upperLimit":"85"},{"groupId":"BG001","value":"67","lowerLimit":"27","upperLimit":"79"},{"groupId":"BG002","value":"67","lowerLimit":"55","upperLimit":"75"},{"groupId":"BG003","value":"67","lowerLimit":"54","upperLimit":"85"},{"groupId":"BG004","value":"66","lowerLimit":"27","upperLimit":"85"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"17"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"23"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"3"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"4"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"16"},{"groupId":"BG004","value":"31"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"40"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"To Evaluate the Safety of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumors.","description":"To determine the Frequency of treatment-emergent adverse events (TEAEs), and serious adverse events (SAEs) related to APR-246 in combination with pembrolizumab.","populationDescription":"Data is presented by cohort/arm. 3 out of the 40 overall patients did not receive treatment on study. 37 total patients were analyzed","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Through study completion, approximately 1 year","groups":[{"id":"OG000","title":"Experimental: Safety Lead In","description":"Patients with advanced solid tumors. APR 4.5 g/day intravenously (IV) on days 1-4 with pembrolizumab 200 mg IV on day 3 in each 21-day cycle"},{"id":"OG001","title":"Experimental: Expansion 1","description":"Patients with advanced gastric cancer. APR 4.5 g/day intravenously (IV) on days 1-4 with pembrolizumab 200 mg IV on day 3 in each 21-day cycle"},{"id":"OG002","title":"Experimental: Expansion 2","description":"Patients with advanced urothelial/bladder cancer. APR 4.5 g/day intravenously (IV) on days 1-4 with pembrolizumab 200 mg IV on day 3 in each 21-day cycle"},{"id":"OG003","title":"Experimental: Expansion 3","description":"Patients with advanced NSCLC. APR 4.5 g/day intravenously (IV) on days 1-4 with pembrolizumab 200 mg IV on day 3 in each 21-day cycle"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"20"}]}]}]},{"type":"PRIMARY","title":"To Confirm the Recommended Phase 2 Dose (RP2D) for APR-246 in Combination With Pembrolizumab","description":"To determine the dose of APR-246 to be selected for the expansion phase based on the occurence of dose limiting toxicities (DLTs) experienced during the safety assessment period","populationDescription":"Experimental: Safety Lead In\" Arm/Group was analyzed for this Outcome Measure","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"g/d","timeFrame":"Through safety lead in period, during cycle 1 (approximately 21 days)","groups":[{"id":"OG000","title":"Experimental: Safety Lead In","description":"Patients with advanced solid tumors. APR 4.5 g/day intravenously (IV) on days 1-4 with pembrolizumab 200 mg IV on day 3 in each 21-day cycle"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"13 months","description":"Data is presented by overall study enrollment and not by cohort.","eventGroups":[{"id":"EG000","title":"Experimental: Safety Lead In","description":"Patients with advanced solid tumors. APR 4.5 g/day intravenously (IV) on days 1-4 with pembrolizumab 200 mg IV on day 3 in each 21-day cycle","deathsNumAffected":5,"deathsNumAtRisk":6,"seriousNumAffected":1,"seriousNumAtRisk":6,"otherNumAffected":6,"otherNumAtRisk":6},{"id":"EG001","title":"Experimental: Expansion 1","description":"Patients with advanced gastric cancer. APR 4.5 g/day intravenously (IV) on days 1-4 with pembrolizumab 200 mg IV on day 3 in each 21-day cycle","deathsNumAffected":4,"deathsNumAtRisk":6,"seriousNumAffected":4,"seriousNumAtRisk":6,"otherNumAffected":5,"otherNumAtRisk":6},{"id":"EG002","title":"Experimental: Expansion 2","description":"Patients with advanced urothelial/bladder cancer. APR 4.5 g/day intravenously (IV) on days 1-4 with pembrolizumab 200 mg IV on day 3 in each 21-day cycle","deathsNumAffected":2,"deathsNumAtRisk":5,"seriousNumAffected":3,"seriousNumAtRisk":5,"otherNumAffected":5,"otherNumAtRisk":5},{"id":"EG003","title":"Experimental: Expansion 3","description":"Patients with advanced NSCLC. APR 4.5 g/day intravenously (IV) on days 1-4 with pembrolizumab 200 mg IV on day 3 in each 21-day cycle","deathsNumAffected":10,"deathsNumAtRisk":20,"seriousNumAffected":7,"seriousNumAtRisk":20,"otherNumAffected":20,"otherNumAtRisk":20}],"seriousEvents":[{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":3,"numAtRisk":20}]},{"term":"Pulmonary Embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":2,"numAtRisk":20}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Respiratory Failure","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Disease Progression","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Pain","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Asthenia","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Pyrexia","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Abdominal Pain upper","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Hypotension","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Embolism","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Blood bilirubin Increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Blood Creatinine increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Acute Kidney Injury","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Atrial Fibraltion","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Hyperbilirubinemia","organSystem":"Hepatobiliary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Urinary tract Infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Hypernatraemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Dizziness","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Confusional State","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Pelvic Pain","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]}],"otherEvents":[{"term":"Nasuea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":6},{"groupId":"EG001","numAffected":2,"numAtRisk":6},{"groupId":"EG002","numAffected":4,"numAtRisk":5},{"groupId":"EG003","numAffected":6,"numAtRisk":20}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":4,"numAtRisk":5},{"groupId":"EG003","numAffected":6,"numAtRisk":20}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":3,"numAtRisk":5},{"groupId":"EG003","numAffected":5,"numAtRisk":20}]},{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":3,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Proctalgia","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":2,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Retching","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":2,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":2,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":2,"numAtRisk":6},{"groupId":"EG002","numAffected":3,"numAtRisk":5},{"groupId":"EG003","numAffected":2,"numAtRisk":20}]},{"term":"Dizziness","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":4,"numAtRisk":5},{"groupId":"EG003","numAffected":9,"numAtRisk":20}]},{"term":"Tremor","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":2,"numAtRisk":20}]},{"term":"Headache","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":2,"numAtRisk":5},{"groupId":"EG003","numAffected":2,"numAtRisk":20}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":2,"numAtRisk":20}]},{"term":"Somnolence","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":2,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Decreased Appetite","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6},{"groupId":"EG001","numAffected":3,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":6,"numAtRisk":20}]},{"term":"Hyponatremia","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":2,"numAtRisk":5},{"groupId":"EG003","numAffected":3,"numAtRisk":20}]},{"term":"Hyperglycemia","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":3,"numAtRisk":20}]},{"term":"Dehydration","organSystem":"Pregnancy, puerperium and perinatal conditions","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":2,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":2,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Malnutrition","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":2,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Fatigue","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":4,"numAtRisk":5},{"groupId":"EG003","numAffected":3,"numAtRisk":20}]},{"term":"Pyrexia","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":2,"numAtRisk":5},{"groupId":"EG003","numAffected":2,"numAtRisk":20}]},{"term":"Asthenia","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Chills","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":2,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Disease progression","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Oedema Peripheral","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Pain","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":6,"numAtRisk":20}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Pulmonary Embolisim","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":2,"numAtRisk":20}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":2,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":2,"numAtRisk":20}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":3,"numAtRisk":20}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":2,"numAtRisk":20}]},{"term":"Blood creatinine increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Blood thyroid stimulating hormone increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Muscular Weakness","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":3,"numAtRisk":20}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":2,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":3,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":4,"numAtRisk":5},{"groupId":"EG003","numAffected":3,"numAtRisk":20}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":2,"numAtRisk":20}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":2,"numAtRisk":20}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Hypotension","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":2,"numAtRisk":20}]},{"term":"Hypertension","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":3,"numAtRisk":20}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":3,"numAtRisk":20}]},{"term":"Atrial Fibrillation","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":2,"numAtRisk":20}]},{"term":"Sinus Tachycardia","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":2,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Acute Kidney Injury","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]},{"term":"Vision Blurred","organSystem":"Eye disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":2,"numAtRisk":20}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":20}]},{"term":"Abdominal Pain Upper","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":20}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"pointOfContact":{"title":"Senior Medical Advisor","organization":"Aprea Therapeutics","email":"info@aprea.com","phone":"215-948-4119"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2020-03-13","uploadDate":"2024-02-27T13:19","filename":"Prot_SAP_000.pdf","size":714854}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2024-03-26","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D001749","term":"Urinary Bladder Neoplasms"},{"id":"D013274","term":"Stomach Neoplasms"},{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D002295","term":"Carcinoma, Transitional Cell"}],"ancestors":[{"id":"D014571","term":"Urologic Neoplasms"},{"id":"D014565","term":"Urogenital Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D001745","term":"Urinary Bladder Diseases"},{"id":"D014570","term":"Urologic Diseases"},{"id":"D052801","term":"Male Urogenital Diseases"},{"id":"D005770","term":"Gastrointestinal Neoplasms"},{"id":"D004067","term":"Digestive System Neoplasms"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D005767","term":"Gastrointestinal Diseases"},{"id":"D013272","term":"Stomach Diseases"},{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D002277","term":"Carcinoma"},{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D009370","term":"Neoplasms by Histologic Type"}]},"interventionBrowseModule":{"meshes":[{"id":"C533410","term":"eprenetapopt"},{"id":"C582435","term":"pembrolizumab"}]}},"hasResults":true}